Integral Health Asset Management’s Denali Therapeutics DNLI Stock Holding History

Integral Health Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-325,000	Closed	-$7.55M	–	72
2024 Q2	$7.55M	Buy	+325,000	New	+$6.24M	0.72%	45
2022 Q4	–	Sell	-115,000	Closed	-$3.53M	–	74
2022 Q3	$3.53M	Buy	+115,000	New	+$3.74M	0.69%	49
2022 Q2	–	Sell	-26,000	Closed	-$836K	–	71
2022 Q1	$836K	Sell	26,000 -74,000	-74%	-$2.55M	0.22%	67
2021 Q4	$4.46M	Buy	100,000 +25,000	+33%	+$1.18M	1.23%	30
2021 Q3	$3.78M	Sell	75,000 -6,000	-7%	-$338K	1.09%	36
2021 Q2	$6.35M	Sell	81,000 -16,000	-16%	-$990K	1.75%	22
2021 Q1	$5.54M	Buy	97,000 +39,500	+69%	+$2.64M	1.58%	25
2020 Q4	$4.82M	Sell	57,500 -107,500	-65%	-$6.5M	1.43%	27
2020 Q3	$5.91M	Buy	165,000 +35,000	+27%	+$1.05M	1.81%	19
2020 Q2	$3.14M	Buy	130,000 +40,000	+44%	+$940K	0.94%	43
2020 Q1	$1.58M	Buy	+90,000	New	+$1.88M	0.69%	44

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Integral Health Asset Management's DNLI Position: Q3 2024 in Review

Integral Health Asset Management sold out of Denali Therapeutics (DNLI) in Q3 2024, closing a stake of 325,000 shares — an estimated $7.55M sold.

Integral Health Asset Management first reported a position in DNLI in Q1 2020 and held it in 11 quarters. The position peaked at $7.55M in Q2 2024. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2024.

Integral Health Asset Management reported no remaining Denali Therapeutics position as of Q3 2024 after selling out during the quarter.
Integral Health Asset Management sold 325,000 Denali Therapeutics shares in Q3 2024, an estimated $7.55M.
Integral Health Asset Management first reported a position in Denali Therapeutics in Q1 2020 and held it in 11 quarters.
Integral Health Asset Management's Denali Therapeutics position peaked at $7.55M in Q2 2024.
217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2024.

Based on Integral Health Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.